Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNLHAC)

• Drug Name: Allopregnanolone Drug Info
• Synonyms: 516-54-1; Brexanolone; Allotetrahydroprogesterone; Allopregnan-3alpha-ol-20-one; 3alpha-hydroxy-5alpha-pregnan-20-one; SAGE-547; UNII-S39XZ5QV8Y; 3-alpha,5-alpha-Pregnanolone; 3alpha-OH DHP; 3alpha,5alpha-THP; 5alpha-Pregnan-3alpha-ol-20-one; 3a-Hydroxy-5a-pregnan-20-one; 3a,5a-THP; (3alpha)-Allopregnanolone; 3-alpha,5-alpha-Tetrahydroprogesterone; BRN 3211363; S39XZ5QV8Y; 3alpha-Hydroxy-5alpha-dihydroprogesterone; 3-alpha-Hydroxy-5-alpha-pregnan-20-one; CHEMBL207538; CHEBI:50169; SGE-102

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Approved	[1]
Postpartum depression	6E20.0	Approved	[1]
Status epilepticus seizure	8A66.1Y	Phase 3	[2]
Essential tremor or related tremors	8A04.1	Phase 2	[3]

• Cross-matching ID:
  PubChem CID: 92786
  ChEBI ID: CHEBI:50169
  CAS Number: CAS 516-54-1
  TTD Drug ID: DMNLHAC
  INTEDE Drug ID: DR0226
  ACDINA Drug ID: D00891

Molecule-Related Drug Atlas

Drug(s) Targeting GABA(A) receptor gamma-2 (GABRG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[8]
ZK-93423	DMFWMKZ	Epileptic seizures	8A61-8A6Z	Phase 3	[9]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[8]
ELTANOLONE	DM38CIV	Premenstrual syndrome	GA34.40	Discontinued in Phase 3	[4]
U-78875	DM2WOPX	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 1	[10]
CGS-9896	DM39PQI	N. A.	N. A.	Terminated	[11]
CGS-17867A	DMMZJY3	Alcohol dependence	6C40.2	Terminated	[12]
TBPS	DMFC3XP	Discovery agent	N.A.	Investigative	[13]
AMENTOFLAVONE	DMLRNV2	Discovery agent	N.A.	Investigative	[14]
Ro-15-3505	DM4NW3U	Discovery agent	N.A.	Investigative	[15]

Drug(s) Targeting GABA(A) receptor delta (GABRD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gaboxadol	DMI53FU	Insomnia	7A00-7A0Z	Approved	[16]
Ganaxolone	DMXJMKF	Epileptic seizures	8A61-8A6Z	Approved	[17]
SAGE-217b	DMRFK0B	Major depressive disorder	6A70.3	Phase 2	[1]
PF-4480682	DMWYJHC	Neuropathic pain	8E43.0	Discontinued in Phase 2	[18]
PF-2393296	DM5R2MG	Neuropathic pain	8E43.0	Discontinued in Phase 1	[19]
Co-60549	DMGIZHX	Anxiety disorder	6B00-6B0Z	Terminated	[20]
Org-20599	DMQU8AR	Anaesthesia	9A78.6	Terminated	[21]
TBPS	DMFC3XP	Discovery agent	N.A.	Investigative	[19]
RU-5135	DMCASRD	Discovery agent	N.A.	Investigative	[22]

Drug(s) Targeting GABA(A) receptor gamma-3 (GABRG3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolpidem	DMWOSKJ	Insomnia	7A00-7A0Z	Approved	[23]
Clobazam - Lundbeck	DMW1OQ0	Anxiety disorder	6B00-6B0Z	Approved	[24]
Flumazenil	DMPCG2L	Benzodiazepine overdose	PC91	Approved	[23]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[25]
Thiamylal	DMHDF7B	Anaesthesia	9A78.6	Approved	[24]
Ganaxolone	DMXJMKF	Epileptic seizures	8A61-8A6Z	Approved	[5]
Mebutamate	DM0KYI4	Anxiety disorder	6B00-6B0Z	Approved	[24]
Metharbital	DM5A38V	Epilepsy	8A60-8A68	Approved	[24]
Etomidate	DMZI3WO	Anaesthesia	9A78.6	Approved	[24]
Remimazolam	DMLVSYX	Procedural sedation	JB0C.3	Approved	[26]

Drug(s) Targeting GABA(A) receptor alpha-1 (GABRA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[27]
Zolpidem	DMWOSKJ	Insomnia	7A00-7A0Z	Approved	[28]
Methoxyflurane	DML0RAE	Anaesthesia	9A78.6	Approved	[27]
Nitrazepam	DMEGIQ6	Epilepsy	8A60-8A68	Approved	[27]
Clobazam - Lundbeck	DMW1OQ0	Anxiety disorder	6B00-6B0Z	Approved	[27]
Hexobarbital	DMQ314B	Anaesthesia	9A78.6	Approved	[27]
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[8]
Meprobamate	DMHM93Y	Anxiety		Approved	[27]
Zaleplon	DMGFWSM	Insomnia	7A00-7A0Z	Approved	[24]
Ethchlorvynol	DM53IP1	Insomnia	7A00-7A0Z	Approved	[27]

Drug(s) Targeting Gamma-aminobutyric acid receptor (GAR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[27]
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[8]
Clonazepam	DMTO13J	Absence epilepsy		Approved	[29]
Piperazine	DMTY9LU	Ascariasis	1F62	Approved	[30]
Alpidem	DMN7Y9K	Anxiety disorder	6B00-6B0Z	Approved	[31]
Moxidectin	DMYGHX5	Onchocerciasis	1F6A	Approved	[32]
DP-VPA	DMGOXPQ	Bipolar disorder	6A60	Approved	[33]
ANDROSTERONE	DMITJAK	N. A.	N. A.	Phase 3	[6]
ZK-93423	DMFWMKZ	Epileptic seizures	8A61-8A6Z	Phase 3	[9]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[8]

Drug(s) Targeting GABA(A) receptor beta-2 (GABRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[8]
Ethchlorvynol	DM53IP1	Insomnia	7A00-7A0Z	Approved	[27]
ZK-93423	DMFWMKZ	Epileptic seizures	8A61-8A6Z	Phase 3	[9]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[8]
ELTANOLONE	DM38CIV	Premenstrual syndrome	GA34.40	Discontinued in Phase 3	[4]
U-78875	DM2WOPX	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 1	[34]
CGS-9896	DM39PQI	N. A.	N. A.	Terminated	[11]
TBPS	DMFC3XP	Discovery agent	N.A.	Investigative	[35]
AMENTOFLAVONE	DMLRNV2	Discovery agent	N.A.	Investigative	[14]
Ro-15-3505	DM4NW3U	Discovery agent	N.A.	Investigative	[15]

Drug(s) Metabolized By Aldo-keto reductase 1B1 (AKR1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
FENOFIBRIC ACID	DMGO2MC	Cardiovascular disease	BA00-BE2Z	Approved	[36]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
GABA(A) receptor alpha-1 (GABRA1)	TT1MPAY	GBRA1_HUMAN	Inhibitor	[4]
GABA(A) receptor beta-2 (GABRB2)	TTZA1NY	GBRB2_HUMAN	Inhibitor	[4]
GABA(A) receptor delta (GABRD)	TTGXH6N	GBRD_HUMAN	Inhibitor	[1]
GABA(A) receptor gamma-2 (GABRG2)	TT06RH5	GBRG2_HUMAN	Inhibitor	[4]
GABA(A) receptor gamma-3 (GABRG3)	TTEX6LM	GBRG3_HUMAN	Modulator	[5]
Gamma-aminobutyric acid receptor (GAR)	TTNJYV2	NOUNIPROTAC	Inhibitor	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Aldo-keto reductase 1B1 (AKR1B1) Main DME	DE7WS3H	ALDR_HUMAN	Substrate	[7]

References

• [1] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605.
• [7] FDA Label of Brexanolone. The 2020 official website of the U.S. Food and Drug Administration.
• [8] 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
• [9] Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9.
• [10] 3-Phenyl-substituted imidazo[1,5-alpha]quinoxalin-4-ones and imidazo[1,5-alpha]quinoxaline ureas that have high affinity at the GABAA/benzodiazepin... J Med Chem. 1996 Sep 13;39(19):3820-36.
• [11] Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66.
• [12] 2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally selective benzodiazepine binding site ligands on the GABAA receptor. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3441-4.
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 414).
• [14] Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4.
• [15] Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
• [16] Gaboxadol--a new awakening in sleep.Curr Opin Pharmacol.2006 Feb;6(1):30-6.
• [17] Ganaxolone, a selective, high-affinity steroid modulator of the gamma-aminobutyric acid-A receptor, exacerbates seizures in animal models of absence. Ann Neurol. 1998 Oct;44(4):688-91.
• [18] WO patent application no. 2014,1515,17, Methods of improving microvascular integrity.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 416).
• [20] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007012)
• [21] The anaesthetic action and modulation of GABAA receptor activity by the novel water-soluble aminosteroid Org 20599. Neuropharmacology. 1996;35(9-10):1209-22.
• [22] Complex interactions between the steroid derivative RU 5135 and the GABAA-receptor complex. Eur J Pharmacol. 1992 Oct 1;227(2):147-51.
• [23] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
• [24] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [25] Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia. 2006 Apr;47(4):704-16.
• [26] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [27] DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
• [28] Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat.Brain Res Bull.2006 Dec 11;71(1-3):200-7.
• [29] Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
• [30] Cyclooctadepsipeptides--an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents. 2003 Sep;22(3):318-31.
• [31] Synthesis and binding affinity of 2-phenylimidazo[1,2-alpha]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new se... J Med Chem. 1997 Sep 12;40(19):3109-18.
• [32] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [33] DP-VPA D-Pharm. Curr Opin Investig Drugs. 2002 Jun;3(6):921-3.
• [34] High-affinity alpha-aminobutyric acid A/benzodiazepine ligands: synthesis and structure-activity relationship studies of a new series of tetracycli... J Med Chem. 1996 Nov 8;39(23):4654-66.
• [35] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 411).
• [36] In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8.